Trials / Unknown
UnknownNCT03172676
Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura
Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
Thrombocytopenia refers to a reduction in platelet count to (\<150 × 109/L). Immune thrombocytopenic purpura is an acquired autoimmune disorder defined by isolated thrombocytopenia and the exclusion of other causes of thrombocytopenia
Detailed description
Helicobacter pylori was recently demonstrated as an etiological factor in immune thrombocytopenic purpura in some prospective studies, with reports of platelet numbers increasing in these patients after Helicobacter pylori eradication treatment.However, other studies have shown a negative result after eradication treatment of Helicobacter pylori infection in patients with chronic immune thrombocytopenic purpura, leading to controversy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days. | chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days. |
| DRUG | Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days. | chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days. |
| DRUG | Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month | chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-06-01
- Completion
- 2020-08-30
- First posted
- 2017-06-01
- Last updated
- 2020-01-03
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03172676. Inclusion in this directory is not an endorsement.